Cerebral thrombotic complications in adolescent leukemia/lymphoma patients treated with L-asparaginase-containing chemotherapy.
We described the cerebral thrombotic complications developed in 2 adolescent patients treated with L-asparaginase-containing regimens. For determining risk factors, we retrospectively analysed hemostatic markers in 19 pediatric patients with leukemia or lymphoma who were treated with either 1 of the 2 L-asparaginase-containing regimens; 11 were treated with VLP1 and the remaining 8 were treated with the VLAD protocol. The data indicated that low coagulation factors in association with increased plasma D-dimer levels during or post-L-asparaginase administration combined with fresh frozen plasma infusion might have activated coagulation processes in these patients. Careful management is required to prevent such episodes in patients with markedly decreased coagulation factors and increased D-dimer levels following L-asparaginase administration.
Imamura
Toshihiko
T
Department of Pediatrics, Kyoto Prefectural University of Medicine, 465 Kajii-cho Hirokoji Kamigyo-ku, Kyoto, Japan. imamura@koto.kpu-m.ac.jp
Morimoto
Akira
A
Kato
Ryuichi
R
Izumi
Moriatu
M
Murakami
Aki
A
Matuo
Satoshi
S
Kiyosawa
Nobuyuki
N
Kano
Gen
G
Yoshioka
Hiroshi
H
Sugimoto
Tohru
T
Imashuku
Shinsaku
S
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000990:Antithrombin III / Q000008:administration & dosage; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000096:biosynthesis; D006801:Humans; D007223:Infant; D020767:Intracranial Thrombosis / Q000097:blood / Q000139:chemically induced*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy*; D008297:Male; D010949:Plasma; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy*; D012189:Retrospective Studies; D012307:Risk Factors
D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D000990:Antithrombin III; D001215:Asparaginase